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Abstract. Background: During the woman’s fertile period,
the non-pregnant uterus is subject to constant cyclic
changes. The complex mechanisms that control the balance
among proliferation, differentiation, cell death and the
structural remodeling of the extracellular matrix can
contribute to the benign or malignant endometrial
pathological state. The small leucine-rich proteoglycans
(SLRPs) are important components of cell surface and
extracellular matrices. Materials and Methods: Using
immunohistochemistry, we showed that the distribution
patterns of SLRPs were completely modified in the
pathological compared to normal endometrium. Results:
The expression of SLRPs was low/absent in all endometrial
pathologies examined compared to normal endometrium. We
observed an increase of lumican from proliferative to
secretory phase of the endometrium and a decrease of
fibromodulin, biglycan and decorin. In menopause
endometrial tissue, the level of expression of fibromodulin,
biglycan, decorin and lumican dramatically decreased.
Conclusion: The results revealed the prominence and
importance of proteoglycans in the tissue architecture and
extracellular matrix organization.
Proteoglycans consist of a large family of highly anionic
glycoproteins ubiquitously expressed in connective tissues (1-5).
Proteoglycans are sub-divided into two groups, large molecules,
such as aggrecan, versican and perlecan, and the relatively small
leucine-rich proteoglycan (SLRP) molecules consisting of five
distinct members, such as fibromodulin (FMOD), biglycan,
decorin, lumican and chondroadherin, containing leucine-rich
repeat motifs in their protein cores (6-8). 
The large proteoglycans help maintain tissue hydration
and contribute to overall structural scaffolding in the
extracellular matrix (ECM), whereas small molecules play
important roles in binding to other matrix molecules, either
aiding fibrillogenesis or acting as bridging molecules among
various tissue elements (1). 
Several studies provide insight concerning the
participation of collagens and proteoglycans in the epithelial-
mesenchymal interface (9, 10). Proteoglycans have been
observed in the cytoplasm of several organs as lung, kidney,
liver, colon, ovary, corneal stroma (11, 12), in the endothelial
cells of small and large vessels, in the structure of the
subcutaneous adipocytes (13) and in the composition of the
articular disc (14, 15). Sometimes the interactions between
growth factors and connective tissue may be causes of
remodelling and pathological states (16, 17). 
An emerging function of SLRPs is an intrinsic ability to
affect cellular proliferation. For example, ectopic expression
of decorin slows-down the growth of a wide variety of tumor
cells. The decorin-induced growth arrest is associated with
an induction of p21, a potent inhibitor of cyclin-dependent
kinase activity (18-20). 
The human endometrium, during every reproductive
cycle, undergoes extensive tissue remodeling in response to
cyclical hormonal changes. Estrogens stimulate
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proliferation and re-establishment of the stromal and
vascular components of the tissue. By contrast, glandular
differentiation and stromal decidualization result from the
influence of progesterone (21). Menstruation is finally
initiated by the fall in estrogen and progesterone that results
from the demise of the corpus luteum at the end of a non-
fertile cycle (22, 23). 
Deregulation of the balance occurring among cellular
proliferation, differentiation and death predisposes
endometrial cells to malignant transformation as in
neoplastic and pre-neoplastic lesions. In recent years,
increasing evidence has highlighted the proteoglycans'
pathway in extracellular matrix remodeling. Changes in
proteoglycan concentration and/or structure may correlate to
changes in the overall architecture of the tissue, possibly
affecting cell proliferation in different ways, such as cell
adhesion, migration and cytokine availability. 
On light of these observations, we investigated the
distribution of the small leucine-rich proteoglycans (SLRPs)
extracellular matrix components in normal endometrium,
obtained from fertile patients and from patients in menopause.
Then, we compared these data with the distribution of these
proteins in different endometrial pathologies, such as
hyperplasia and polyps through histochemical methods. 
Materials and Methods
Samples. Human endometrial samples were obtained under the
approval of an appropriate ethics committee from patients undergoing
surgery, such as laparotomic hysterectomy, colpohysterectomy and
operative hysteroscopy. A total of 15 samples of physiological
endometrium (5 in proliferative phase, 5 in secretory phase and 5 in
menopause) (Table I) and 10 samples of pathological endometrium (5
of hyperplasia, 5 of post-menopausal polyps) (Table II) were used for
the study. Removal of endometrial samples, both physiological and
pathological, was carried-out by different surgical instruments (novak,
courette and bipolar loop). The specimens, picked under sterile
conditions with different instruments, were immediately fixed in
formalin for immunohistochemistry.
Immunohistochemistry. Immunohistochemistry was carried-out
essentially as described previously (24-26). Briefly, sections from
each specimen were cut at 5 μm, mounted on glass and dried
overnight at 37˚C. All sections were then deparaffinized in xylene,
rehydrated through a graded series of alcohol and washed in
phosphate-buffered saline (PBS). PBS was used for all subsequent
washes and for antiserum dilution. Tissue sections were quenched
sequentially in 3% hydrogen peroxide and blocked with PBS–6%
non-fat dry milk (Bio-Rad Laboratories S.r.l. Milano, Italy) for 1 h
at room temperature. Slides were then incubated at 4˚C overnight
with antibodies raised against human fibromodulin, biglycan,
decorin and lumican (Santa Cruz Biotechnology, Dallas, TX, USA),
each at a 1:100 dilution. After several washes (3×5min) to remove
excess antibody, the slides were incubated with diluted (1:200) anti-
goat biotinylated antibodies (Vector Laboratories, Burlington, ON
Canada) for 1 h. All the slides were then processed by the ABC
method (Vector Laboratories) for 30 min at room temperature. 3, 3'-
diaminobenzidine (DAB; Vector Laboratories) was used as a
chromogen and hematoxylin was used as a nuclear counter stain.
For each antibody, negative controls were prepared by substituting
the primary antiserum with non-immune IgG and positive controls
by using the antibody on a tissue section where the protein had
already been demonstrated.
For each experiment, all the slides were stained in a single batch,
thus ensuring equal staining for each. The staining pattern of
fibromodulin, biglycan, decorin and lumican proteins were
examined and scored for staining intensity signal: 0 (absent
immunopositivity); 1 (low immunopositivity); 2 (moderate
immunopositivity); 3 (intense immunopositivity) (27).
For each specimen, a HSCORE value was derived by summing the
percentages of cells/areas that stained at each intensity and multiplying
that by the weighted intensity of the staining. For example:
HSCORE=ΣPi(i + 1)
where i represents the intensity scores and Pi the corresponding
percentage of cells/areas. An average of 22 fields was observed for
each tissue by three observers at different times and the average
score was used. All values were expressed as mean±standard error
of mean (S.E.M.) and differences were compared using the
Student’s t-test.
Results
In the present study we describe the distribution of the
SLRPs in the physiological and in the pathological
endometrium. 
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Table I. Sampling of physiological endometrium.
Number of patients 15
Average age (years) 49.8
Endometrium Proliferative phase  5
Secretory phase 5
Menopause  5





Table II. Sampling of pathological endometrium.
Number of patients 10
Average age (years) 42.8
Endometrial pathology Polyps 5
Hyperplasia 5





In Figure 1 the expression of the SRLPs (fibromodulin,
biglycan, lumican and decorin) is depicted as detected by
immunohistochemical staining intensity analysis. Student’s
t-test revealed significant score × immunopositivity
differences (p<0.05) for fibromodulin, biglycan, lumican and
decorin expression levels in the different physiological
endometrial phases and pathological endometrium. In detail,
we observed that the distribution patterns of SLRPs were
completely modified in the pathological endometrium
compared to normal endometrium. 
Our results showed that the expression of biglycan and
lumican was low in endometrial pathologies (polyps and
hyperplasia), whereas the expression of fibromodulin and
decorin was absent in the endometrial pathologies (polyps
and hyperplasia) compared to normal endometrium.
Instead, in physiological endometrium, we observed a
different modulation and localization of the SRLPs. 
Fibromodulin: Fibromodulin showed a low level of
expression in the endometrium stroma during the
proliferative phase (Figure 2a). In the secretory phase, we
observed an increase of fibromodulin immunopositivity at a
low/moderate level of expression; it was localized especially
in the apical portion of endometrial glands (Figure 2b). 
Biglycan: During the proliferative phase, biglycan showed
a moderate/intense immunopositivity in the basement
membrane of the vessel (Figure 2c). In the secretory phase,
we observed a low level of expression of biglycan in all the
endometrial compartments (Figure 2d). 
Lumican: In the samples examined, we observed that, in
the proliferative phase, lumican was expressed at moderate
levels in some epithelial cells and the vessel wall (Figure 2e).
During the secretory phase, lumican expression increased at
a moderate/intense level with a particular localization in the
stroma and in the apical portion of endometrial glands
(Figure 2f).
Decorin: In the samples examined, we observed that, both
in the proliferative and secretive phases, the decorin
expression level was very low (data not shown).
Expression of fibromodulin, biglycan, lumican and
decorin was almost absent in all components of the
endometrium in menopause (data not shown).
Discussion
The switch from proliferation to differentiation is a process that
requires growth factors and the cross-talk among different
cellular pathways. The binding of growth factors to
proteoglycans and the subsequent modulation of growth factor
activities represent one of the major conceptual advances in the
field; whether this binding is mediated by the protein core or
the carbohydrate moiety, the final event is a perturbation (either
negative or positive) of the growth factors' biological activity
with significant consequences on the affected cell population.
Moreover, this biological interaction provides a mechanistic
explanation for the growth- and differentiation-promoting
ability of the extracellular matrix.
Proteoglycans and glycosaminoglycans have been studied
in uterine cells in culture and in normal uterus, especially
during pregnancy (28-30), but there are few reports on
proteoglycans in uterine pathology.
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Figure 1. Expression pattern of small leucine rich proteoglycan proteins in human endometrium during physiological reproductive cycle and in
human pathological endometrium. Vertical lines show means±SEM.
In the present study we described the distribution of SLRPs
in the physiological endometrium and in the pathological
endometrium. To determine if the changes in proteoglycan
expression correlate with modifications in the extracellular
matrix organization, we compared the general architecture of
physiological endometrium to the pathological endometrium.
Through immunohistochemistry, we showed that the
distribution patterns of SLRPs were completely modified in
the pathological endometrium compared to normal
endometrium. Our results showed that the expression SLRPs
was low/absent in all the endometrial pathologies examined
compared to normal endometrium. We observed an increase
of lumican from proliferative to secretory phase of the
endometrium and a decrease of fibromodulin, biglycan and
decorin. In menopause endometrial tissue, the level of
expression of fibromodulin, biglycan, decorin and lumican
dramatically decreased. 
Our data demonstrated a change in the tissue
architecture and extracellular matrix organization in the
compartment examined. Our data are supported by a
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Figure 2. Localization of small leucine rich proteoglycan proteins in human endometrium during the physiological reproductive cycle. (a)
Fibromodulin low expression during the proliferative phase; ×300; (b) Fibromodulin low/moderate immunopositivity in the apical portion of
endometrial glands during the secretory phase; ×300; (c) Biglycan moderate/intense immunopositivity in the basemant membrane of the vessel
during the proliferative phase; ×300; (d) Biglycan low expression in the endometrial compartments during the secretory phase; ×640; (e) Lumican
moderate immunopositivity in some epithelial cells and vessel wall of the proliferative phase; ×640; (f) Lumican moderate/intense immunoreactivity
in the stroma and in the apical portion of endometrial glands in the secretory phase; ×300. 
previous report that demonstrated, in “knockout” mice, that
absence of decorin results in lax, fragile skin in which
collagen fibril morphology is irregular with fusion of
adjacent fibrils appearing to have occurred (31). Absence
of biglycan resulted in an osteoporosis-like phenotype,
with animals having a reduced growth rate and a decreased
bone mass (32). Absence of lumican produced both skin
laxity and corneal opacity with an increased proportion of
abnormally thick collagen fibrils and delayed corneal
epithelial wound healing (33). Absence of fibromodulin
produced no change in the appearance of te mice but it was
possible to observe an abnormal collagen fibril
organization in tendons (34). This work clearly shows that
collagen fibril architecture is impaired in tissues in which
SLRPs are deficient and that the abnormal phenotype is
specific for each proteoglycan.
Instead, at the molecular level, increased transforming
growth factor beta (TGF-b) production is the hallmark of a
number of fibrotic diseases that are characterized by
abundant accumulation of extracellular matrix components.
At least four SLRP members (fibromodulin, biglycan,
lumican and decorin,) interact with TGF-b (35). These in
vitro binding studies correlate well with the observation that
ectopic expression of decorin leads to marked growth
retardation and change in morphology and adhesion
properties of TGF-b-dependent cells (36). Moreover, several
lines of evidence support a specific protein/protein
interaction between decorin and epidermal growth factor
receptor (EGFR) (37). Because decorin and other SLRP
members are intimately associated with fibrillar collagen, a
complex picture in which multimeric interactions take place
in an integrin-independent manner should be considered. An
enhancement in decorin content in the newly-formed tumor
stroma could trigger functional interaction with EGFR,
which would, in turn, start a signaling cascade that directly
influences the cell-cycle machinery. In this light, it is
noteworthy that a double knockout of decorin and p53, a
well-established tumor suppressor gene, shows a cooperative
action between these two genes and an acceleration of
lymphoma tumorigenesis (38). 
In summary, the results presented herein reveal the
importance of proteoglycans in the tissue architecture and
extracellular matrix organization. Changes in matrix
composition may be related to modifications in the tissue
architecture that lead to alterations in several biological
phenomena concerning the control of cell proliferation, such
as growth factor and cytokine availability, cell adhesion and
migration, as well as immune response.
SLRPs are involved both in the regulation and the
organization of the connective tissue and control of cell
growth; their lack of expression could explain the
disorganization of the support tissue and, in the long run,
phenomena as the uncontrolled growth of tissue.
Conflicts of Interest
The Authors declare that they have no conflicts of interest.
Acknowledgements
The Authors would like to thank Dr. Pia Furno for editorial
assistance.
References
1 Yanagishita M: Function of proteoglycans in the extracellular
matrix. Acta Pathol Jpn 43: 283-293, 1993.
2 Hildebrand A, Romaris M, Rasmussen LM, Heinegard D,
Twardzik DR, Border WAandRuoslahti E: Interaction of the
small interstitial proteoglycans biglycan, decorin and
fibromodulin with transforming growth factor beta. Biochem J
302: 527-534, 1994.
3 Burton-Wurster N, Liu W, Matthews GL, Lust G, Roughley PJ,
Glant TT and Cs-Szabo G: TGF beta 1 and biglycan, decorin,
and fibromodulin metabolism in canine cartilage. Osteoarthritis
Cartilage 11: 167-176, 2003.
4 Melrose J, Ghosh P and Taylor TK: A comparative analysis of
the differential spatial and temporal distributions of the large
(aggrecan, versican) and small (decorin, biglycan, fibromodulin)
proteoglycans of the intervertebral disc. J Anat 198: 3-15, 2001.
5 Kinsella MG, Bressler SL and Wight TN: The regulated
synthesis of versican, decorin, and biglycan: extracellular matrix
proteoglycans that influence cellular phenotype. Crit Rev
Eukaryot Gene Expr 14: 203-234, 2004.
6 Blochberger TC, Vergnes JP, Hempel J and Hassell JR: cDNA
to chick lumican (corneal keratan sulfate proteoglycan) reveals
homology to the small interstitial proteoglycan gene family and
expression in muscle and intestine. J Biol Chem 267: 347-352,
1992.
7 Noonan DDand Hassell JR: Perlecan, the large low-density
proteoglycan of basement membranes: structure and variant
forms. Kidney Int 43: 53-60, 1993.
8 Neame PJ, Sommarin Y, Boynton RE and Heinegård D: The
structure of a 38-kD leucine-rich protein (chondroadherin)
isolated from bovine cartilage. J Biol Chem 269: 21547-21554,
1994.
9 Godoy-Guzmán C, San Martin S and Pereda J: Proteoglycan and
collagen expression during human air conducting system
development. Eur J Histochem Jun 29; 56(3), 2012.
10 Stabellini G, Calvitti M, Baroni T, Marinucci L, Calastrini C,
Carinci Pand Becchetti E: Glycosidases during chick embryo
lung development and their colocalization with proteoglycans
and growth factors. Eur J Histochem 46(1): 41-52, 2002.
11 Carrillo LM, Arciniegas E, Rojas H and Ramírez R:
Immunolocalization of endocan during the endothelial-
mesenchymal transition process. Eur J Histochem 55(2): e13, 2011.
12 Raspanti M, Congiu T, Alessandrini A, Gobbi Pand Ruggeri A:
Different patterns of collagen-proteoglycan interaction: a
scanning electron microscopy and atomic force microscopy
study. Eur J Histochem 44(4): 335-343, 2000.
13 Pierleoni C, Verdenelli F, Castellucci Mand Cinti S: Fibronectins
and basal lamina molecules expression in human subcutaneous
white adipose tissue. Eur J Histochem 42(3): 183-188, 1998.
Lucariello et al: Distribution of Proteoglycans in the Endometrium
221
14 Kiga N: Histochemistry for studying structure and function of
the articular disc of the human temporomandibular joint. Eur J
Histochem Feb 29; 56(1), 2012.
15 Kiga N, Tojyo I, Matsumoto T, Hiraishi Y, Shinohara Y and
Fujita S: Expression of lumican in the articular disc of the
human temporomandibular joint. Eur J Histochem Jul 8, 54(3):
e11, 2010.
16 Kiga N, Tojyo I, Matsumoto T, Hiraishi Y, Shinohara Y, Makino
S and Fujita S. Expression of lumican and fibromodulin
following interleukin-1 beta stimulation of disc cells of the
human temporomandibular joint. Eur J Histochem 55(2): e11,
2011.
17 Carinci P, Becchetti E, Baroni T, Carinci F, Pezzetti F, Stabellini
G, Locci P, Scapoli L, Tognon M, Volinia S and Bodo M:
Extracellular matrix and growth factors in the pathogenesis of
some craniofacial malformations. Eur J Histochem 51(Suppl 1):
105-115, 2007.
18 Santra M, Skorski T, Calabretta B, Lattime ECand Iozzo RV: De
novo decorin gene expression suppresses de malignant
phenotype in human colon cancer cells. Proc Natl Acad Sci USA
92: 7016-7020, 1995.
19 Santra M, Mann DM, Mercer EW, Skorski T, Calabretta Band
Iozzo RV: Ectopic expression of decorin protein core causes a
generalized growth suppression in neoplastic cells of various
histogenetic origin and requires endogenous p21, an inhibitor of
cyclin- dependent kinases. J. Clin. Invest 100: 149-157, 1997.
20 De Luca A, Santra M, Baldi A, Giordano A and Iozzo RV:
Decorin induced growth suppression is associated with up-
regulation of p21, an inhibitor of cyclin-dependent kinases. J.
Biol. Chem 271: 18961-18965, 1996.
21 Csermely T, Demers LMand Hughes EC: Organ culture of
human endometrium. Effects of progesterone. Obstet Gyneco 34:
252-259, 1969.
22 Critchley HO, Tong S, Cameron ST, Drudy TA, Kelly RWand
Baird DT: Regulation of bcl-2 gene family members in human
endometrium by antiprogestin administration in vivo. J Reprod
Fertil 115: 389-395, 1999.
23 Salamonsen LA and Lathbury LJ: Endometrial leukocytes and
menstruation. Hum Reprod Update 6: 16-27, 2000.
24 Cobellis L, Caprio F, Trabucco E, Mastrogiacomo A, Coppola
G, Manente L, Colacurci N, De Falco M and De Luca A: The
pattern of expression of Notch protein members in normal and
pathological endometrium. Journal of Anatomy 213: 464-472,
2008.
25 De Falco M, Cobellis L, Torella M, Acone G, Varano L, Sellitti
A, Ragucci A, Coppola G, Cassandro R, Laforgia V, Varano L
and De Luca A: Down-regulation of aquaporin 4 in human
placenta throughout pregnancy. In Vivo 21: 813-817, 2007.
26 Baldi A, De Crescenzo V, Giordano DR, Lamberti R, Perna A,
Picone C, Lucariello A, Feroce F, Grattacaso S and De Luca A:
Cystic nephroma: report of a case and review of the literature.
In Vivo 21: 895-896, 2007.
27 Trabucco E, Soderberg M, Cobellis L, Torella M, Bystrom B,
Ekman-Ordeberg G, Petraglia F and Colacurci N: Role of
proteoglycans in the organization of periurethral connective
tissue in women with stress urinary incontinence Maturitas 58:
395-405, 2007.
28 Cabrol D, Breton M, Berrou E, Visser A, Sureau C and Picard
J: Variations in the distribution of glycosaminoglycans in the
uterine cervix of the pregnant woman. Eur J Obstet Gynecol
Reprod Biol 10: 281-287, 1980.
29 Uldbjerg N, Malmström A, Ekman G, Sheehan J, Ulmsten U and
Wingerup L: Isolation and characterization of dermatan sulphate
proteoglycan from human uterine cervix. J. Biochem 209: 497-
503, 1983.
30 Golichowski AM, King SR and Mascaro K: Pregnancy-related
changes in rat cervical glycosaminoglycans. Biochem J 192: 1-
8, 1980.
31 Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE,
and Iozzo RV: Targeted disruption of decorin leads to abnormal
collagen fibril morphology and skin fragility. J Cell Biol 136:
729-743, 1997.
32 Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S,
Bonadio J, Boskey A, Heegaard AM, Sommer B, Satomura K,
Dominguez P, Zhao C, Kulkarni AB, Gehron Robey Pand Young
MF: Targeted disruption of the biglycan gene leads to an osteo-
porosis-like phenotype in mice. Nature Genet 20: 78-82, 1998.
33 Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia Cand
Carroll H: Lumican regulates collagen fibril assembly: skin
fragility and corneal opacity in the absence of lumican. J Cell
Biol 141: 1277-1286, 1998.
34 Svensson L, Aszodi A, Reinholt FP, Fassler R, Heinegard D and
Oldberg A: Fibromodulin-null mice have abnormal collagen
fibrils, tissue organization, and altered lumican deposition in
tendon. J Biol Chem 274: 9636-9647, 1999.
35 Hildebrand A, Romaris M, Rasmussen LM, Heinegård D,
Twardzik DR, Border WA and Ruoslahti E: Interaction of the
small interstitial proteoglycans biglycan, decorin and
fibromodulin with transforming growth factor beta. Biochem J
302: 527-534, 1994.
36 Yamaguchi Y, Mann DM and Ruoslahti E: Nagative regulation
of trasforming growth factor-beta by the proteoglycan decorin.
Nature 346: 281-284, 1990.
37 Iozzo RV, Moscatello D, McQuillan DJand Eichstetter I: Decorin
is a biological ligand for the epidermal growth factor receptor. J
Biol Chem 274: 4489-4492, 1999.
38 Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T,
Calabretta B and Eichstetter I: Cooperative action of germ-line
mutations in decorin and p53 accelerates lymphoma
tumorigenesis. Proc Natl Acad Sci USA 96: 3092-3097, 1999.
Received January 23, 2015
Revised February 6, 2015
Accepted February 9, 2015
in vivo 29: 217-222 (2015)
222
